icon - ideas

European Medicines Agency

blue background, white text

Regulatory data and market exclusivity: What will change with the new pharmaceutical regulation? 

In this blog, we explore the current EU framework for regulatory data exclusivity and market exclusivity, examine the proposed legislative changes, and discuss what these reforms could mean for pharmaceutical and biotechnology […]

blue background, white text

How will the revised pharmaceutical legislation change paediatric drug development?

In this blog, we explore the current EU paediatric medicine development framework, examine the proposed legislative changes, and discuss the potential impact on medicine developers who must include paediatric studies in their medicine development programmes and get […]

blue background, white text

How will the revised pharmaceutical regulation change the EMA’s Priority Medicines (PRIME) scheme? 

In this blog, we explore the current PRIME framework, examine how the revised pharmaceutical legislation may impact the scheme, and discuss what these changes could mean for medicine developers navigating the evolving EU regulatory […]

How will the revised pharmaceutical legislation change orphan-designated medicines for rare diseases

How will the revised pharmaceutical legislation change orphan-designated medicines for rare diseases? 

In this blog, we explore the current EU orphan designation framework, examine the proposed legislative changes, and discuss the potential impact on medicine developers pursuing orphan medicinal product designation and approval in […]

monthly roundup

Regulatory Roundup: News & Publications in Pharma and Biotech in January 2026

Each month, we scan the regulatory landscape to bring you the latest developments shaping pharmaceutical and biotechnology innovation. In this roundup, you’ll find key publications that caught our attention, plus a curated […]

Comparing EU, UK and US Regulatory Approached to Orphan Drugs

Comparing EU, UK and US Regulatory Approaches to Orphan Drugs

EMA, MHRA, and FDA: A Comparative Guide to Orphan Drug Regulations and how they affect medicine developers.

European Clinical Trials After the CTD to CTR Transition: What Changed and What Three Years of Data Reveal

European Clinical Trials After the CTD to CTR Transition: What Changed and What Three Years of Data Reveal

The transition from the Clinical Trials Directive (CTD) to the Clinical Trials Regulation (CTR) caused quite a stir for pharmaceutical companies, biotech’s, clinical research organisations, and those of us in regulatory affairs. […]

How the EMA’s Revised CTIS Transparency Rules Affect Clinical Trial Sponsors

How the EMA’s Revised CTIS Transparency Rules Affect Clinical Trial Sponsors

This blog explores the EMA’s revised CTIS transparency rules, the increase in clinical trial transitions to the Clinical Trial Regulation (CTR), and how the new publication framework (introduced in June 2024) aimed […]

blue and white images with words

What has changed in the Priority Medicines (PRIME) scheme? 

The European Medicines Agency's (EMA) Priority Medicines (PRIME) scheme offers early regulatory support to accelerate the development of innovative medicines addressing unmet medical needs. In 2023, the EMA introduced several new features […]

EMA new fees

The EMA’s new fees: What does the new fee regulation mean for medicine developers?

The fees payable to the EMA will follow the current legal framework until December 31st, 2024. Then, as of January 1st, 2025, the new fee regulation (EU 2024/568) will be implemented.